Logo image of DRTS

ALPHA TAU MEDICAL LTD (DRTS) Stock Fundamental Analysis

NASDAQ:DRTS - Nasdaq - IL0011839383 - Common Stock - Currency: USD

3  +0.03 (+1.01%)

Fundamental Rating

2

DRTS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. DRTS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DRTS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

DRTS had negative earnings in the past year.
DRTS had a negative operating cash flow in the past year.
In the past 5 years DRTS always reported negative net income.
DRTS had a negative operating cash flow in each of the past 5 years.
DRTS Yearly Net Income VS EBIT VS OCF VS FCFDRTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

DRTS has a Return On Assets of -36.83%. This is in the lower half of the industry: DRTS underperforms 61.50% of its industry peers.
DRTS has a Return On Equity (-50.67%) which is in line with its industry peers.
Industry RankSector Rank
ROA -36.83%
ROE -50.67%
ROIC N/A
ROA(3y)-30.7%
ROA(5y)-34.69%
ROE(3y)-39.04%
ROE(5y)-55.73%
ROIC(3y)N/A
ROIC(5y)N/A
DRTS Yearly ROA, ROE, ROICDRTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DRTS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DRTS Yearly Profit, Operating, Gross MarginsDRTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for DRTS has been increased compared to 1 year ago.
DRTS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, DRTS has a worse debt to assets ratio.
DRTS Yearly Shares OutstandingDRTS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
DRTS Yearly Total Debt VS Total AssetsDRTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

DRTS has an Altman-Z score of 3.41. This indicates that DRTS is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.41, DRTS is doing good in the industry, outperforming 71.12% of the companies in the same industry.
DRTS has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
DRTS has a better Debt to Equity ratio (0.09) than 60.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 3.41
ROIC/WACCN/A
WACCN/A
DRTS Yearly LT Debt VS Equity VS FCFDRTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

DRTS has a Current Ratio of 7.40. This indicates that DRTS is financially healthy and has no problem in meeting its short term obligations.
DRTS has a Current ratio of 7.40. This is amongst the best in the industry. DRTS outperforms 87.70% of its industry peers.
A Quick Ratio of 7.40 indicates that DRTS has no problem at all paying its short term obligations.
DRTS has a Quick ratio of 7.40. This is amongst the best in the industry. DRTS outperforms 89.30% of its industry peers.
Industry RankSector Rank
Current Ratio 7.4
Quick Ratio 7.4
DRTS Yearly Current Assets VS Current LiabilitesDRTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for DRTS have decreased strongly by -12.20% in the last year.
EPS 1Y (TTM)-12.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, DRTS will show a very strong growth in Earnings Per Share. The EPS will grow by 25.30% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-6.65%
EPS Next 2Y10%
EPS Next 3Y7.78%
EPS Next 5Y25.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DRTS Yearly Revenue VS EstimatesDRTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
DRTS Yearly EPS VS EstimatesDRTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DRTS. In the last year negative earnings were reported.
Also next year DRTS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRTS Price Earnings VS Forward Price EarningsDRTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRTS Per share dataDRTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10%
EPS Next 3Y7.78%

More info and screens

0

5. Dividend

5.1 Amount

DRTS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALPHA TAU MEDICAL LTD

NASDAQ:DRTS (6/25/2025, 8:00:02 PM)

3

+0.03 (+1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-19 2025-05-19/amc
Earnings (Next)N/A N/A
Inst Owners1.79%
Inst Owner Change13.34%
Ins Owners16.26%
Ins Owner ChangeN/A
Market Cap254.10M
Analysts86
Price Target8.93 (197.67%)
Short Float %0.17%
Short Ratio2.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.71%
Min EPS beat(2)-5.04%
Max EPS beat(2)18.47%
EPS beat(4)3
Avg EPS beat(4)10.43%
Min EPS beat(4)-5.04%
Max EPS beat(4)18.47%
EPS beat(8)6
Avg EPS beat(8)11.89%
EPS beat(12)9
Avg EPS beat(12)-27.32%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.32%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.75%
EPS NY rev (1m)4.56%
EPS NY rev (3m)-0.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.05
P/tB 4.05
EV/EBITDA N/A
EPS(TTM)-0.46
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0
BVpS0.74
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.83%
ROE -50.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.7%
ROA(5y)-34.69%
ROE(3y)-39.04%
ROE(5y)-55.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 203.09%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.4
Quick Ratio 7.4
Altman-Z 3.41
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)296.97%
Cap/Depr(5y)1091.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
EPS Next Y-6.65%
EPS Next 2Y10%
EPS Next 3Y7.78%
EPS Next 5Y25.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.78%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.16%
OCF growth 3YN/A
OCF growth 5YN/A